

Coagadex® (coagulation Factor X [human]) – Expanded indication

- On April 14, 2023, the <u>FDA approved</u> Bio Products Laboratory's <u>Coagadex (coagulation Factor X [human])</u>, in adults and children with hereditary Factor X deficiency for perioperative management of bleeding in patients with mild, moderate, and severe hereditary Factor X deficiency.
 - Coagadex was previously approved for this indication in patients with mild and moderate Factor X deficiency.
- Coagadex is also approved in adults and children with hereditary Factor X deficiency for:
 - Routine prophylaxis to reduce the frequency of bleeding episodes
 - On-demand treatment and control of bleeding episodes.
- The approval of Coagadex for the expanded indication was based on a post-marketing registry study in 3 patients (aged 21 to 30 years) with severe hereditary Factor X deficiency. Patients received a total of 10 doses of Coagadex for perioperative hemostatic cover.
 - The median initial (pre-surgery) dose was 44.3 IU/kg (mean 40.6; range 28.6 to 48.9). A median of 4 (range 1 to 5) infusions was administered, with median cumulative dose 110.2 IU/kg (range 28.6 to 171.8).
 - All three patients achieved excellent hemostatic efficacy outcomes.
- Refer to the Coagadex for complete dosing and administration recommendations.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.